Advancements in the Management of R/R AML: ASH 2024 - Episode 1
Treatment Strategies for Relapsed/Refractory AML Patients
Panelists discuss how the latest NCCN guidelines for relapsed/refractory acute monocytic leukemia (R/R AML) outline targeted therapy options outside clinical trials, and explore treatment approaches based on patient fitness, actionable biomarkers, and prior therapies, highlighting the impact of first remission duration and genetic abnormalities on treatment sequencing.
Video content above is prompted by the following:
- Briefly review targeted therapy options outside of a clinical trial for relapsed/refractory AML according to the latest NCCN guidelines.
- What is your treatment approach for those R/R patients who are fit enough for an aggressive chemotherapy-based regimen, but also have an actionable biomarker?
- How does length of first remission play into that decision-making and/or whether they have already gone through allo-HSCT?
- On the other hand, for those R/R AML patients who received a previous “lower-intensity therapy” such as venetoclax-based therapy or IDH1-based therapy, what is your typical treatment sequencing?
- How does it differ between those with a genetic abnormality and those who do not?
Related Content:
